Mineralocorticoid-receptor antagonism with the novel drug finerenone reduces the risk of new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes mellitus, according to a secondary analysis of the FIDELIO-DKD trial.

中文翻译：

---

Finerenone 可预防 CKD 和糖尿病患者的心房颤动

根据对 FIDELIO-DKD 试验的二次分析，新型药物finerenone 的盐皮质激素受体拮抗作用可降低慢性肾病和 2 型糖尿病患者新发心房颤动或扑动的风险。